Effect of Combined Ultrasound-guided Subdeltoid Corticosteroid Injections and Physiotherapy in Treatment of Patients With Chronic Subacromial Bursitis

Sponsor
Shin Kong Wu Ho-Su Memorial Hospital (Other)
Overall Status
Completed
CT.gov ID
NCT03871465
Collaborator
Ministry of Science and Technology, Taiwan (Other)
111
1
3
24
4.6

Study Details

Study Description

Brief Summary

This study is to investigate whether combination of ultrasound-guided subdeltoidcorticosteroid injection and physiotherapy is more effective than either treatment alone in treatment of patients with chronic subacromial (or subdeltoid) bursitis (SAB).

Condition or Disease Intervention/Treatment Phase
  • Drug: Triamcinolone SASD injection
  • Procedure: Physiotherapy
  • Drug: Triamcinolone injections & Physiotherapy
N/A

Detailed Description

Chronic subacromial bursitis (SAB) is a common shoulder disorder characterized by chronic shoulder pain with a painful arc of motion, and/or pain on active or passive motions. The diagnosis of SAB requires confirmation by an infiltration with local anesthetic. Previous study showed that corticosteroid injection is more effective than hyaluronic acid in treatment of chronic SAB, however, some (about 20%) patients were not responsive to corticosteroid injection, and some responsive patients may have recurrence of symptoms. The purpose of this study is to investigate whether combination of corticosteroids SASD injections and physiotherapy is more effective than either treatment alone in chronic SAB.

Study Design

Study Type:
Interventional
Actual Enrollment :
111 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Double (Participant, Investigator)
Primary Purpose:
Treatment
Official Title:
Effect of Combined Ultrasound-guided Subdeltoid Corticosteroid Injections and Physiotherapy in Treatment of Patients With Chronic Subacromial Bursitis
Actual Study Start Date :
Aug 1, 2018
Actual Primary Completion Date :
Jul 31, 2020
Actual Study Completion Date :
Jul 31, 2020

Arms and Interventions

Arm Intervention/Treatment
Experimental: Triamcinolone SASD injection

2ml triamcinolone (1ml/10mg) and 3ml 1% xylocain will be injected into the affected SASD bursa under ultrasound guidance.

Drug: Triamcinolone SASD injection
2ml triamcinolone (1ml/10mg) and 3ml 1% xylocain will be injected into the affected SASD bursa under ultrasound guidance.

Experimental: Physiotherapy

The physiotherapy program consists of hot pack, interferential therapy, and exercise program, which includes stretch exercise, mobilization of the glenohumeral joint, manual pressure to the possible trigger points, scapular stabilization exercise, and strengthening exercise of the rotator cuff, trapezius, and serratus anterior muscles.

Procedure: Physiotherapy
The physiotherapy program consists of hot pack, interferential therapy, and exercise program, which includes stretch exercise, mobilization of the glenohumeral joint, manual pressure to the possible trigger points, scapular stabilization exercise, and strengthening exercise of the rotator cuff, trapezius, and serratus anterior muscles.

Experimental: Triamcinolone injections & Physiotherapy

2ml triamcinolone (1ml/10mg) and 3ml 1% xylocain will be injected into the affected SASD bursa under ultrasound guidance. The physiotherapy program consists of hot pack, interferential therapy, and exercise program, which includes stretch exercise, mobilization of the glenohumeral joint, manual pressure to the possible trigger points, scapular stabilization exercise, and strengthening exercise of the rotator cuff, trapezius, and serratus anterior muscles.

Drug: Triamcinolone injections & Physiotherapy
2ml triamcinolone (1ml/10mg) and 3ml 1% xylocain will be injected into the affected SASD bursa under ultrasound guidance. The physiotherapy program consists of hot pack, interferential therapy, and exercise program, which includes stretch exercise, mobilization of the glenohumeral joint, manual pressure to the possible trigger points, scapular stabilization exercise, and strengthening exercise of the rotator cuff, trapezius, and serratus anterior muscles.

Outcome Measures

Primary Outcome Measures

  1. The pain VAS score [change between baseline and at 8 weeks after the beginning of the treatment.]

    The pain VAS score is obtained using a 100-mm-long horizontal line, with 0 mm on the left indicating no pain and 100 mm on the right indicating very severe pain.

  2. The scores of the Shoulder Pain and Disability Index (SPADI) [change between baseline and at 8 weeks after the beginning of the treatment.]

    The total SPADI score, which ranges between 0 and 100, is calculated by averaging the scores from the pain and disabilities subclasses.

Secondary Outcome Measures

  1. The active ROM [change between baseline and at 8 weeks after the beginning of the treatment.]

    The maximal active ROMs of the affected shoulder will be measured using a goniometer under the guidelines of the American Academy of Orthopedic Surgeons. These measurements included abduction in the frontal plane, forward flexion, internal rotation, and external rotation with the arm at 0 degrees of abduction.

  2. Change of the Shoulder Disability Questionnaire (SDQ) [change between baseline and at 8 weeks after the beginning of the treatment.]

    The SDQ is a symptoms-related questionnaire containing 16 items describing common situations that may induce symptoms in patients with shoulder disorders. By responding 'yes', 'no', or 'not applicable', the final score is obtained by dividing the number of positively scored items by the total number of applicable items and then multiplying this number by 100, which results in a final score ranging between 0 (no disability) and 100 (the worst situation).

  3. The Western Ontario Rotator Cuff Index (WORC). [change between baseline and at 8 weeks after the beginning of the treatment.]

    It is composed of 5 subscales: physical symptoms, sports/recreation, work, lifestyle, and emotions. Each item has a score range of 0 to 100.Scores can be computed for individual subscales and summated for a total score, which can range from 0-2100, with a higher score representing lower quality of life.

Eligibility Criteria

Criteria

Ages Eligible for Study:
20 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  1. shoulder pain for more than 1 month

  2. age ≥20 years old

  3. painful abduction or internal rotation with a visual analog scale (VAS) pain score ≥4

  4. the presence of a painful arc of motion or pain at the middle to terminal range of shoulder abduction or internal rotation with an empty or soft end feel

  5. positive shoulder impingement test (Neer test and/or Hawkin test)

  6. a reduction in pain of ≥40% on active shoulder abduction or internal rotation at the terminal range after injection of 3ml of 1%lidocain into the SASD bursa under US guidance.

Exclusion Criteria:
  1. a history of uncontrolled chronic diseases, e.g., malignant neoplasms, blood dyscrasia, and serious infection

  2. previous surgery of the affected shoulder

  3. any evidence of a rotator cuff tear or tendinopathy, demonstrated by positive resistive tests andsonographic findings

  4. calcification of the rotator cuff, demonstrated by x-ray or sonographic findings

  5. the presence of arthritis, such asinflammatory arthritis(e.g., rheumatoid arthritis, seronegativespondyloarthropathy, or crystal-related arthropathy), osteoarthritis, frozen shoulder, subacromial spurs, or deformity of the acromion

  6. the presence of instability of the affected shoulder

  7. a previous fracture near the shoulder region

  8. the presence of cervical radiculopathy or myelopathy

  9. having received a corticosteroid or hyaluronic acid subacromial or shoulder joint injection in the past 3 months.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Shin Kong Wu Ho-Su Memorial Hospital Taipei Taiwan

Sponsors and Collaborators

  • Shin Kong Wu Ho-Su Memorial Hospital
  • Ministry of Science and Technology, Taiwan

Investigators

  • Principal Investigator: Lin-Fen Hsieh, Shin Kong Wu Ho-Su Memorial Hospital

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Shin Kong Wu Ho-Su Memorial Hospital
ClinicalTrials.gov Identifier:
NCT03871465
Other Study ID Numbers:
  • 20171205R
  • MOST 107-2314-B-341-002
  • MOST 108-2314-B-341-002
First Posted:
Mar 12, 2019
Last Update Posted:
Feb 9, 2022
Last Verified:
Feb 1, 2022
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Shin Kong Wu Ho-Su Memorial Hospital
Additional relevant MeSH terms:

Study Results

No Results Posted as of Feb 9, 2022